Skip to main content

Table 3 Summary of Week 12 and Week 52 predictive factors of response in CZP-treated patients

From: Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

Response

Week 12

Week 52

ASDAS-MI

- Younger age

- Male sex

- Elevated CRP

- Higher PtGADA at baseline

- MRI+/HLA-B27+

- Higher BASDAI at baseline

- Greater Week 12 ASDAS improvement

ASAS40

- Younger age

- Male sex

- MRI+/HLA-B27+

- Lower BASMI at baseline

- Greater Week 12 PtGADA and ASQoL improvements

BASDAI50

- Younger age

- Male sex

- MRI+/HLA-B27+

- MASES = 0

- Greater Week 12 BASDAI and ASQoL improvements

ASDAS-ID

- Younger age

- Male sex

- Positive MRI

- ≤2 prior NSAIDs

- ASDAS-ID at Week 12

- Lower BASFI at baseline

- Greater Week 12 BASDAI improvement

  1. ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), ASQoL Ankylosing Spondylitis Quality of Life, BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, BASMI Bath Ankylosing Spondylitis Metrology Index, HLA-B27 human leukocyte antigen-B27, MRI magnetic resonance imaging, MASES Maastricht Ankylosing Spondylitis Enthesitis Score (range 0−13), NSAID non-steroidal anti-inflammatory drug, PtGADA Patient Global Assessment of Disease Activity